ISPOR - PSK1 COST EFFECTIVENESS OF THE USE OF INFLIXIMAB COMPARED TO OTHER BIOLOGICAL AGENTS (BA) IN THE SYSTEMIC TREATMENT OF MODERATE TO SEVERE PSORIASIS

Full Text

PSK1 COST EFFECTIVENESS OF THE USE OF INFLIXIMAB COMPARED TO OTHER BIOLOGICAL AGENTS (BA) IN THE SYSTEMIC TREATMENT OF MODERATE TO SEVERE PSORIASIS

Abstract

Authors

M Fonseca G Araujo

Back to Volume 10, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now